Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year High – Here’s Why

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) shares reached a new 52-week high on Wednesday . The company traded as high as $12.97 and last traded at $12.84, with a volume of 2141273 shares changing hands. The stock had previously closed at $12.82.

Wall Street Analyst Weigh In

AMRX has been the subject of several recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, October 8th. JPMorgan Chase & Co. raised their price objective on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Piper Sandler restated an “overweight” rating and issued a $13.00 price objective (up from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st. Finally, Barclays assumed coverage on Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price on the stock. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Amneal Pharmaceuticals Stock Up 0.9%

The firm has a 50-day moving average price of $11.69 and a two-hundred day moving average price of $9.90. The firm has a market cap of $4.07 billion, a PE ratio of 648.07 and a beta of 1.36.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.12 by $0.05. The firm had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. Research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Activity

In other Amneal Pharmaceuticals news, EVP Nikita Shah sold 131,856 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total value of $1,571,723.52. Following the transaction, the executive vice president directly owned 146,403 shares of the company’s stock, valued at $1,745,123.76. This trade represents a 47.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ted C. Nark sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the transaction, the director owned 291,029 shares in the company, valued at approximately $3,410,859.88. This represents a 14.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 231,856 shares of company stock worth $2,743,724. Insiders own 26.56% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Comerica Bank increased its holdings in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares during the last quarter. Exchange Traded Concepts LLC purchased a new position in Amneal Pharmaceuticals in the third quarter worth approximately $31,000. Focus Partners Wealth acquired a new stake in Amneal Pharmaceuticals during the third quarter worth $42,000. Advisory Services Network LLC purchased a new stake in Amneal Pharmaceuticals in the third quarter valued at $50,000. Finally, Bellevue Group AG acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $79,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.